Retatrutide is a powerful triple agonist peptide that targets GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors—making it the most comprehensive metabolic peptide in its class. It builds on the progress of earlier compounds like Semaglutide and Tirzepatide by activating three key hormonal pathways involved in appetite regulation, glucose control, and fat metabolism.

This enhanced activity leads to while offering additional therapeutic effects across multiple body systems.

​

MECHANISM OF ACTION

• GLP-1 Receptor Agonist: Slows gastric emptying, reduces appetite, regulates insulin secretion

• GIP Receptor Agonist: Enhances insulin release, improves glucose tolerance, improve fat metabolism

• Glucagon Receptor Agonist: Stimulates energy expenditure and promotes fat breakdown (lipolysis)

​

CLINICAL EFFECTIVENESS

• Semaglutide (GLP-1 only): 17% average body weight loss after 68 weeks

• Tirzepatide (GLP-1 + GIP): 24.7% body weight loss after 72 weeks

• Retatrutide (GLP-1 + GIP + Glucagon):

  • 17.5% average weight loss in just 24 weeks

  • 26.2% average loss in only 48 weeks

This rapid and sustained weight reduction places Retatrutide as the most effective peptide currently being studied for metabolic disorders and fat loss.

​

ADDITIONAL BENEFITS

• Anti-inflammatory: May assist with autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease

• Collagen Support: Promotes epithelialization and collagen synthesis, enhancing skin tone and elasticity

• Wound Healing: Accelerates post-injury tissue regeneration

• Angiogenesis: Encourages the formation of new blood vessels to improve circulation and tissue oxygenation

• Muscle Regeneration: Activates satellite cells for muscle growth and repair

​

EMERGING THERAPEUTIC APPLICATIONS

Beyond weight loss and glucose control, Retatrutide is being explored for a wide array of research purposes:

• Cardiovascular Health: May reduce risk factors like hypertension, cholesterol imbalance, and vascular inflammation

• Sleep & Addiction: Potential role in treating sleep apnea, substance use disorders, and depression

​

POSSIBLE SIDE EFFECTS

Common (Mild to Moderate):

• Nausea

• Vomiting

• Headache

• Indigestion

• Constipation or diarrhea

• Abdominal discomfort

• Dehydration

Rare but Serious:

• Gallbladder issues (e.g., gallstones)

• Pancreatitis

• Severe allergic reaction

• Intestinal blockages

• Gastroparesis (delayed stomach emptying)

• Dehydration-induced kidney strain (especially in those with existing kidney disease)

​

 Important: Most side effects are dose-dependent and time-dependent. Higher doses over long durations increase risk. These effects can be minimized with proper stacking, hydration, and dosage planning.

​

MANAGING SIDE EFFECTS

• Avoid fatty or greasy foods

• Maintain consistent hydration

• Stop eating once full — satiety occurs earlier on GLP-1/GIP peptides

• Dose at night

• Use fiber supplements to avoid constipation

• If the standard dosing protocol causes you too many side effects, it can be amended to allow you to start at less than the typical dose, and to increase gradually in smaller increments rather than following the 2mg increase all at once after 4 weeks. Consult staff for assistance

​

INTERACTIONS

• Other GLP’s: leads to a risk of increased pancreatitis and premature desensitization

• Insulin or Insulin Secretagogues (e.g. glipizide, glyburide): risk of developing hypoglycemia

• Oral Medications: delayed gastric emptying effects absorption over oral contraceptives, antibiotics, thyroid meds (levothyroxine), stimulants, and pain medications

USE CAUTION/SEEK MEDICAL SUPERVISION IF…

• You have a history of pancreatitis

• You have a history of gallbladder disease

• You have a severe gastrointestinal disorder (e.g. gastroparesis)

​

CONTRAINDICATIONS

Do NOT use Retatrutide if…

• You are pregnant or nursing

• You have chronic kidney disease

• You have advanced liver disease

• You have severe gastrointestinal disorders, such as Crohn’s or IBD

• You or a family member has a history of thyroid cancer

• You are allergic or hypersensitive to peptide-based medications

​